Drugs / Toremifen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06495515 | Aug 2024 → Jul 2025 overdue | female breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Toremifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06495515 ↗ |
| Route | Oral | “60mg orally” NCT06495515 ↗ |